FDA Reopens Comment Period For Feedback On Improving The OTC Monograph Process

JD
Jones Day

Contributor

Jones Day is a global law firm with more than 2,500 lawyers across five continents. The Firm is distinguished by a singular tradition of client service; the mutual commitment to, and the seamless collaboration of, a true partnership; formidable legal talent across multiple disciplines and jurisdictions; and shared professional values that focus on client needs.
FDA reopened the comment period for the notice of public hearing, originally published in the February 24, 2014, Federal Register.
United States Food, Drugs, Healthcare, Life Sciences

In the July 1, 2014, Federal Register, FDA reopened the comment period for the notice of public hearing, originally published in the February 24, 2014, Federal Register, requesting comments on how to improve or alter the current Over-the-Counter ("OTC") Monograph Process for reviewing nonprescription drugs marketed under OTC Drug Review. Comments are now due July 31, 2014.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More